Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. News
  7. Summary
    OASM   SE0000722365


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oasmia Pharmaceutical : First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

06/11/2021 | 10:40am EDT

Stockholm, Sweden - Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces that the first patient has been dosed in a Phase 1b clinical trial of Oasmia's Docetaxel micellar in patients with advanced prostate cancer. The trial is being conducted by the Swiss Group for Clinical Cancer Research (SAKK).

Oasmia's Docetaxel micellar is a solvent-free formulation of docetaxel developed to avoid the need for the solubility enhancers in solvent based docetaxel, and the mandatory high-dose steroid premedication, while providing an effective treatment option. Prostate cancer is a significant and increasingly prevalent health problem worldwide and is the leading cause of male cancer deaths.

The SAKK 67/20 trial (NCT04629781) is an open-label, multicenter, single-stage Phase 1b trial at major hospitals in Switzerland, recruiting 18 chemotherapy-naive patients with metastatic castration resistant prostate cancer (mCRPC) with adequate bone marrow, liver and renal function. The primary objective of this trial is to determine the maximum tolerated dose of Docetaxel micellar in patients with mCRPC and the secondary objectives are to evaluate safety, assess the preliminary anti-tumor activity, and to characterize the pharmacokinetics in this population.

The Swiss Group for Clinical Cancer Research (SAKK) is a non-profit organization, which has been conducting clinical trials in oncology since 1965. Its primary objective is to research new cancer therapies, to develop existing treatments further and to improve the chances of a cure for patients with cancer. For more information, please visit www.sakk.ch.

Professor Markus Jorger, President Project Group Developmental Therapeutics at SAKK commented: 'It is a significant step to have dosed the first patient in this Phase 1b trial of Docetaxel micellar in advanced prostate cancer patients. Docetaxel micellar has the potential to remove the need for pretreatment with corticosteroids, thereby not adding more steroid to patients who have had significant prior steroid administration leading to marked bone fragility, exacerbated by cancer metastases in the bone, or may have steroid-related metabolic issues.'

Heidi B. Ramstad, M.D., Chief Medical Officer of Oasmia, commented: 'We are pleased to be partnering with SAKK on this trial which we believe is an important step towards evaluating whether Docetaxel micellar can be a treatment option for patients with advanced prostate cancer, without the mandatory steroid use that is necessary with existing, solvent-based docetaxel formulations.'


Oasmia Pharmaceutical AB

Francois Martelet

Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: IR@oasmia.com

Consilium Strategic Communications


Jonathan Birt

Chris Welsh

Ashley Tapp

Phone: +44 (0)20 3709 5700

E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB

Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Oasmia's most advanced program is Apealea (paclitaxel micellar), which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia's proprietary drug delivery platform XR-17 is designed to improve drug solubility, efficacy and safety. Oasmia's shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.

About SAKK

The Swiss Group for Clinical Cancer Research (SAKK) is a non-profit organization, which has been conducting clinical trials in oncology since 1965. Its primary objective is to research new cancer therapies, to develop existing treatments further and to improve the chances of a cure for patients with cancer. This takes place through cooperative projects within Switzerland and in collaboration with centers and study groups abroad. SAKK is supported by a service-level agreement with the State Secretariat for Education, Research and Innovation (SERI) and also by partners such as the Swiss Cancer League and Swiss Cancer Research. For more information, please visit www.sakk.ch.

(C) 2021 Electronic News Publishing, source ENP Newswire

10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
10/20OASMIA PHARMACEUTICAL : Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutic..
10/08OASMIA PHARMACEUTICAL (OASM) : Focused on pillars of growth
10/01OASMIA PHARMACEUTICAL : Naventus LifeScience Summit
09/24OASMIA PHARMACEUTICAL : to present at Naventus Life Science Summit on September 29
09/20OASMIA PHARMACEUTICAL : Notice of Extraordinary General Meeting in Oasmia Pharmaceutical A..
09/17OASMIA PHARMACEUTICAL : signs agreement with FarmaMondo to commercialize Paclical® in Russ..
09/17Oasmia Pharmaceutical AB Signs Agreement with FarmaMondo to Commercialize Paclical® in ..
09/07OASMIA PHARMACEUTICAL : Presentation på Aktiedagen Stockholm
08/31OASMIA PHARMACEUTICAL : to present at Aktiedagen Stockholm on September 7
More news
Sales 2021 10,2 M 1,19 M 1,19 M
Net income 2021 -173 M -20,1 M -20,1 M
Net cash 2021 130 M 15,1 M 15,1 M
P/E ratio 2021 -5,93x
Yield 2021 -
Capitalization 1 063 M 124 M 124 M
EV / Sales 2021 91,5x
EV / Sales 2022 26,4x
Nbr of Employees 25
Free-Float 61,3%
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,37 SEK
Average target price 5,70 SEK
Spread / Average Target 140%
EPS Revisions
Managers and Directors
François R. Martelet Chief Executive Officer
Fredrik Järrsten Chief Financial Officer
Karl Anders Olof Härfstrand Chairman
Mikael Asp Chief Technology Officer
Carina Eklöw Director-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.83%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.16.27%239 966
NOVO NORDISK A/S56.26%238 738